Skip to main content
SpringerLink
Log in
Book cover

Neuropsychiatric Systemic Lupus Erythematosus pp 141–154Cite as

Treatment of Neuropsychiatric Systemic Lupus Erythematosus

  • Chapter
  • First Online:

  • 660 Accesses

Abstract

Systemic lupus erythematosus includes a wide range of neuropsychiatric manifestations, in which various autoantibodies and cytokines could play a pathophysiologic role. The key drugs used in the treatment of neuropsychiatric systemic lupus erythematosus include corticosteroids and immunosuppressive agents to suppress the underlying inflammatory pathology, antiplatelet and antithrombotic agents in the context of thrombosis mediated by antiphospholipid antibodies, and agents for symptomatic treatment of individual neuropsychiatric manifestations, such as antiepileptic drugs for seizures and antipsychotic drugs for lupus psychosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.

    Article  Google Scholar 

  2. Matus S, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med. 2007;204:3221–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Shiozawa S, et al. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992;35:417–22.

    Article  CAS  PubMed  Google Scholar 

  4. Hirohata S, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319–23.

    Article  PubMed  Google Scholar 

  5. Yoshio T, et al. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus. 2016;25:997–1003.

    Article  CAS  PubMed  Google Scholar 

  6. Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074–82.

    Article  CAS  PubMed  Google Scholar 

  7. Magro-Checa C, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hirohata S, Hirose S, Miyamoto T. Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity. Arch Intern Med. 1985;145:1843–6.

    Article  CAS  PubMed  Google Scholar 

  9. Iizuka N, et al. Identification of autoantigens specific for systemic lupus erythematosus with central nervous system involvement. Lupus. 2010;19:717–26.

    Article  CAS  PubMed  Google Scholar 

  10. Arinuma Y, et al. Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Lupus Sci Med. 2014;1:e000050.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nishimura K, et al. Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: case report. Int J Psychiatry Med. 2003;33:299–303.

    Article  PubMed  Google Scholar 

  12. Fernandes Moca Trevisani V, Castro AA, Ferreira Neves Neto J, Atallah AN. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev. 2013; CD002265.

    Google Scholar 

  13. Barile-Fabris L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kozora E, Filley CM. Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus. J Int Neuropsychol Soc. 2011;17:385–92.

    Article  PubMed  Google Scholar 

  15. Tomietto P, et al. General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 2007;57:1461–72.

    Article  CAS  PubMed  Google Scholar 

  16. Menon S, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–41.

    Article  CAS  PubMed  Google Scholar 

  17. Hanly JG, et al. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728–34.

    Article  CAS  PubMed  Google Scholar 

  18. McLaurin EY, et al. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005;64:297–303.

    Article  CAS  PubMed  Google Scholar 

  19. Denburg SD, et al. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;37:1311–20.

    Article  CAS  PubMed  Google Scholar 

  20. Petri M, et al. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum. 2011;41:194–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Devinsky O, et al. Epilepsy associated with systemic autoimmune disorders. Epilepsy Cur. 2013;13:62–8.

    Article  Google Scholar 

  22. Bluestein HG, et al. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 1981;70:240–6.

    Article  CAS  PubMed  Google Scholar 

  23. Arinuma Y, et al. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008;58:1130–5.

    Article  CAS  PubMed  Google Scholar 

  24. Yoshio T, et al. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol. 2005;32:34–9.

    CAS  PubMed  Google Scholar 

  25. Mitsikostas DD, et al. A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth. Brain. 2004;127(Pt 5):1200–9.

    Article  PubMed  Google Scholar 

  26. Gladman DD, et al. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288–91.

    PubMed  Google Scholar 

  27. Hanly JG, et al. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013;65:2887–97.

    Article  PubMed  Google Scholar 

  28. Dale RC, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Dev Med Child Neurol. 2011;53:522–8.

    Article  PubMed  Google Scholar 

  29. Krakauer M, Law I. FDG PET brain imaging in neuropsychiatric systemic lupus erythematosis with choreic symptoms. Clin Nucl Med. 2009;34:122–3.

    Article  PubMed  Google Scholar 

  30. Bala MM, et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. Cochrane Database Syst Rev. 2017;10:CD012169.

    PubMed  Google Scholar 

  31. Fonseca AG, D'Cruz DP. Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis. 2008;5:6.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Carey RA, et al. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and peri-arteritis nodosa. Bull Johns Hopkins Hosp. 1950;87:425–60.

    CAS  PubMed  Google Scholar 

  33. Pickering G, et al. Treatment of systemic lupus erythematosus with steroids: report to the Medical Research Council by the collagen diseases and hypersensitivity panel. Br Med J. 1961;2:915–20.

    Article  Google Scholar 

  34. Albert DA, et al. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum. 1979;22:945–53.

    Article  CAS  PubMed  Google Scholar 

  35. Buttgereit F, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zhen J, et al. Death-related factors of systemic lupus erythematosus patients associated with the course of disease in Chinese populations: multicenter and retrospective study of 1,958 inpatients. Rheumatol Int. 2013;33(6):1541.

    Article  PubMed  Google Scholar 

  37. Jonsen A, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41:1308–12.

    Article  CAS  PubMed  Google Scholar 

  38. Rubin LA, et al. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med. 1985;55:87–98.

    CAS  PubMed  Google Scholar 

  39. Kasturi S, Sammaritano LR. Corticosteroids in Lupus. Rheum Dis Clin N Am. 2016;42:47–62,viii

    Article  Google Scholar 

  40. Brown ES, et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol. 2002;22:55–61.

    Article  PubMed  Google Scholar 

  41. Shimizu Y, et al. Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev. 2016;15:786–94.

    Article  PubMed  Google Scholar 

  42. Hirohata S, et al. A patient with systemic lupus erythematosus presenting both central nervous system lupus and steroid induced psychosis. J Rheumatol. 1988;15:706–10.

    CAS  PubMed  Google Scholar 

  43. Hebert LA, Rovin BH. Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care? Nephron Clin Pract. 2011;117:c8–14.

    Article  CAS  PubMed  Google Scholar 

  44. Kivity S, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Boumpas DT, et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991;81:975–84.

    Article  CAS  PubMed  Google Scholar 

  46. Neuwelt CM, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med. 1995;98:32–41.

    Article  CAS  PubMed  Google Scholar 

  47. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus–the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol. 1992;19:370–2.

    CAS  PubMed  Google Scholar 

  48. Baca V, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol. 1999;26:432–9.

    CAS  PubMed  Google Scholar 

  49. Martin-Suarez I, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56:481–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ramos PC, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol. 1996;14:295–9.

    CAS  PubMed  Google Scholar 

  51. Stojanovich L, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12:3–7.

    Article  CAS  PubMed  Google Scholar 

  52. Hirano T, et al. Successful therapy with steroid and cyclophosphamide pulse for CNS lupus and lupus myelitis. Jap J Clin Immunol. 2007;30:414–8.

    Article  Google Scholar 

  53. Fanouriakis A, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016;25:627–36.

    Article  CAS  PubMed  Google Scholar 

  54. Gonzalez LA, et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus. 2009;18:822–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Levy Y, et al. A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response. Lupus. 1999;8:705–12.

    Article  CAS  PubMed  Google Scholar 

  56. Sakthiswary R, D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine. 2014;93:e86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Toubi E, et al. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunoly. 2005;66:395–402.

    Article  CAS  Google Scholar 

  58. Milstone AM, et al. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol. 2005;24:394–7.

    Article  PubMed  Google Scholar 

  59. Engel G, van Vollenhoven RF. Treatment of severe CNS lupus with intravenous immunoglobulin. J Clin Rheumatol. 1999; 5:228–32. Sherer Y, et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol. 1999; 18:170–3.

    Google Scholar 

  60. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003;7:173–82.

    Article  PubMed  Google Scholar 

  61. Bartolucci P, et al. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16:817–22.

    Article  CAS  PubMed  Google Scholar 

  62. Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Dooley MA, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95.

    Article  CAS  PubMed  Google Scholar 

  64. Tselios K, et al. Mycophenolate Mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016;43:552–8.

    Article  PubMed  Google Scholar 

  65. Ginzler EM, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010;62:211–21.

    Article  CAS  PubMed  Google Scholar 

  66. Conti F, et al. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. Immunol Res. 2014;60:270–6.

    Article  CAS  PubMed  Google Scholar 

  67. Lhotta K, et al. Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus. 2004;13:139–41.

    Article  CAS  PubMed  Google Scholar 

  68. Jose J, et al. Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci. 2005;59:353–6.

    Article  CAS  PubMed  Google Scholar 

  69. Higashioka K, et al. Successful treatment of lupus cerebrovascular disease with mycophenolate mofetil. Intern Med. 2015;54:2255–9.

    Article  CAS  PubMed  Google Scholar 

  70. Mok CC, et al. Mycophenolate mofetil for lupus related myelopathy. Ann Rheum Dis. 2006;65:971–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Saison J, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2015;24:74–81.

    Article  CAS  PubMed  Google Scholar 

  72. Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57:e1–e45.

    Article  PubMed  Google Scholar 

  73. Feng L, et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology. 2013;18:104–10.

    Article  CAS  PubMed  Google Scholar 

  74. Mok CC, et al. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med. 2003;115:59–62.

    Article  CAS  PubMed  Google Scholar 

  75. Ginzler E, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18:27–34.

    Article  CAS  PubMed  Google Scholar 

  76. Tokunaga M, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–5.

    Article  CAS  PubMed  Google Scholar 

  77. Narvaez J, Rios-Rodriguez V, de la Fuente D, Estrada P, Lopez-Vives L, Gomez-Vaquero C, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364–72.

    Article  CAS  PubMed  Google Scholar 

  78. Dale RC, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Furie R, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Navarra SV, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.

    Article  CAS  PubMed  Google Scholar 

  81. Manzi S, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Hirohata S. 110th scientific meeting of the Japanese society of internal medicine: invited lecture: 5. Neurological involvement in connective tissue diseases. Nippon Naika Gakkai Zasshi. 2013;102:2214–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan

    Tetsuji Sawada

Authors
  1. Tetsuji Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuji Sawada .

Editor information

Editors and Affiliations

  1. Department of Rheumatology, Nobubara Hospital, Tatsuno, Hyogo, Japan

    Shunsei Hirohata

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sawada, T. (2018). Treatment of Neuropsychiatric Systemic Lupus Erythematosus. In: Hirohata, S. (eds) Neuropsychiatric Systemic Lupus Erythematosus. Springer, Cham. https://doi.org/10.1007/978-3-319-76496-2_10

Download citation

Publish with us

Policies and ethics

Search

Navigation